PRISMA |
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement |
MeSH |
Medical subject headings |
WHO |
World Health Organization |
CDC |
Center for Disease Control |
RCT |
Randomized clinical trial |
COVID-19 |
Coronavirus disease 2019 |
alum |
Potassium aluminum sulfate |
VLPs |
Virus-like particles |
ORs |
Odds ratios |
6-HB |
six-helical bundle |
SARS-CoV-2 |
Severe acute respiratory syndrome coronavirus 2 |
95% CI |
95% confidence interval |
GMT |
Geometric mean titer |
RBD |
Receptor-binding domain |
PLpro |
Papain-like proteases |
3CLpro |
Cysteine-like protease |
NAb |
Neutralizing antibody |
Pro-subunit |
Protein subunit |
VLP |
Virus-like particle |
BMI |
Body mass index |
CFR |
Case fatality ratio |
RNA |
Ribonucleic acid |
messenger RNA |
mRNA |
S-protein |
Spike protein |
ACE2 |
Angiotensin-converting enzyme 2 |
nsp |
Non-structural proteins |
IM |
Intramuscular |